FHTX - CIK 0001822462
The table below shows Foghorn Therapeutics Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $87.66M | $89.33M | $72.57M | $61.03M | $57.68M | $138.95M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $188.06M |
| $184.12M |
| $203.84M |
| $225.42M |
| $271.23M |
| $289.62M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $222.17M | $204.96M | $226.24M | $258.69M | $308.37M | $328.58M |
| Accounts payable | $3.32M | $3.21M | $3.32M | $4.07M | $3.45M | $4.81M |
| Total current liabilities | $64.40M | $85.09M | $77.79M | $71.31M | $56.82M | $50.87M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $298.57M | $294.62M | $302.89M | $320.34M | $336.66M | $342.91M |
| Retained earnings | -$652.34M | -$610.80M | -$594.95M | -$577.02M | -$538.68M | -$519.56M |
| Total equity | -$76.41M | -$89.66M | -$76.66M | -$61.65M | -$28.29M | -$14.32M |